BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26617755)

  • 21. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
    Armada L; Marotta Pdos S; Pires FR; Siqueira JF
    J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation.
    Cao H; Wang J; Xi L; Røe OD; Chen Y; Wang D
    Circ J; 2011; 75(12):2781-8. PubMed ID: 22001292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RANK/RANKL/OPG system in the intervertebral disc.
    Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A
    Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology.
    Melchiorre D; Milia AF; Linari S; Romano E; Benelli G; Manetti M; Guiducci S; Ceccarelli C; Innocenti M; Carulli C; Civinini R; Morfini M; Matucci-Cerinic M; Ibba-Manneschi L
    J Rheumatol; 2012 Aug; 39(8):1678-86. PubMed ID: 22753650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
    Cao J; Venton L; Sakata T; Halloran BP
    J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
    Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of bone resorption regulators (RANK, RANKL, and OPG) in odontogenic tumors.
    Andrade FR; Sousa DP; Mendonça EF; Silva TA; Lara VS; Batista AC
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Oct; 106(4):548-55. PubMed ID: 18928898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-energy laser stimulates tooth movement velocity via expression of RANK and RANKL.
    Fujita S; Yamaguchi M; Utsunomiya T; Yamamoto H; Kasai K
    Orthod Craniofac Res; 2008 Aug; 11(3):143-55. PubMed ID: 18713151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
    Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alteration of the RANKL/RANK/OPG System in Periprosthetic Osteolysis with Septic Loosening.
    Wang L; Dai Z; Xie J; Liao H; Lv C; Hu Y
    Inflammation; 2016 Feb; 39(1):218-227. PubMed ID: 26294373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.